• Inventiva published a medical research presentation showing investigational lanifibranor reduced liver fibrosis across preclinical models.
• Balanced pan-PPAR activation improved liver-cell metabolism, dampened macrophage-driven inflammation and supported function across other hepatic cell populations.
• The findings support further development of lanifibranor as an antifibrotic therapy for metabolic dysfunction-associated steatohepatitis (MASH).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inventiva SA published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.